Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
09 nov. 2021 16h14 HE | Catalyst Pharmaceuticals, Inc.
Continued Strong Financial and Operational Performance in the Third Quarter 2021FIRDAPSE® Revenue of $35.9 Million Increased 23.1% Compared to Third Quarter 2020Plans to Seek to Expand the U.S....
KRYS.jpg
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
26 oct. 2021 07h00 HE | Krystal Biotech, Inc.
Topline results anticipated in the fourth quarter of 2021Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021
25 oct. 2021 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
The MDS Foundation Celebrates MDS World Awareness Day With Their 4th Annual Move for MDS 5k Walk at Boston Common and Virtually Around the World
20 oct. 2021 10h05 HE | MDS Foundation, Inc.
YARDVILLE, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- The MDS Foundation, a global non-profit advocacy organization is proud to announce its fourth annual Move for MDS walk at Boston Common on Sunday,...
ambulero_4a.png
Ambulero’s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe Vascular Disease
19 oct. 2021 09h18 HE | Ambulero
MIAMI, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Ambulero Inc., a biotechnology company (“Ambulero” or the “Company”) developing new cell and gene therapy treatments for patients suffering from severe...
Saniona slutför inlämningen till FDA av tillverkningsdata för Tesometkapslar
18 oct. 2021 08h00 HE | Saniona AB
PRESSMEDDELANDE 18 oktober 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att alla uppgifter som det amerikanska...
Saniona completes submission of manufacturing data for Tesomet capsules to U.S. FDA
18 oct. 2021 08h00 HE | Saniona AB
PRESS RELEASE 18 October 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has completed the submission of all information...
Saniona medverkar vid flera kommande digitala investerarkonferenser
06 oct. 2021 08h00 HE | Saniona AB
PRESSMEDDELANDE 6 oktober 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att bolaget kommer att hålla presentationer...
Saniona to participate in multiple upcoming virtual investor conferences
06 oct. 2021 08h00 HE | Saniona AB
PRESS RELEASE 6 October 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it will present at multiple upcoming virtual investor...
logo_ProQR-150x150.png
ProQR Appoints Theresa Heggie as Chief Commercial Officer
04 oct. 2021 08h00 HE | ProQR Therapeutics N.V.
Senior leader with extensive global rare disease commercialization experienceTop-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 ...